Travere Therapeutics (NASDAQ:TVTX) Insider Sells $81,605.58 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,031 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $40.18, for a total value of $81,605.58. Following the sale, the insider owned 86,756 shares of the company’s stock, valued at $3,485,856.08. The trade was a 2.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jula Inrig also recently made the following trade(s):

• On Tuesday, January 6th, Jula Inrig sold 445 shares of Travere Therapeutics stock. The shares were sold at an average price of $37.75, for a total transaction of $16,798.75.
• On Wednesday, December 24th, Jula Inrig sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $630,000.00.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $34.58 on Friday. The firm has a fifty day moving average of $35.72 and a 200-day moving average of $25.88. Travere Therapeutics, Inc. has a 52-week low of $12.91 and a 52-week high of $42.13. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. The firm has a market capitalization of $3.09 billion, a P/E ratio of -32.62, a PEG ratio of 1.25 and a beta of 0.85.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The business had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same quarter in the previous year, the business posted ($0.70) EPS. The business’s quarterly revenue was up 162.1% on a year-over-year basis. As a group, analysts predict that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Stephens Investment Management Group LLC bought a new stake in shares of Travere Therapeutics in the 3rd quarter worth about $38,232,000. Wellington Management Group LLP grew its stake in Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after purchasing an additional 1,166,460 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Travere Therapeutics in the second quarter valued at about $14,831,000. Perceptive Advisors LLC acquired a new stake in Travere Therapeutics during the second quarter valued at approximately $12,347,000. Finally, Marshall Wace LLP bought a new position in Travere Therapeutics during the 2nd quarter worth approximately $10,992,000.

Analyst Ratings Changes

TVTX has been the subject of a number of recent research reports. Wall Street Zen upgraded Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Citigroup upped their price target on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research report on Friday, November 28th. Cowen reissued a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, October 8th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.71.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.